SCHEMBL3144232

SCHEMBL3144232

Cc1ccc(Nc2ncc3c(=O)n(-c4cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc4C)c(=O)n(C)c3n2)c(C)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.56
TNK2 Q07912 10/20 0.56
MAP4K2 Q12851 10/20 0.56
ABL1 P00519 3/20 0.56
BMX P51813 3/20 0.56
BCR P11274 1/20 0.56
RIPK1 Q13546 1/20 0.56
RIPK3 Q9Y572 1/20 0.56
MAPK3 P27361 1/20 0.52
BTK Q06187 4/20 0.49
SRC P12931 4/20 0.49
EPHB4 P54760 2/20 0.49
LCK P06239 2/20 0.49
FES P07332 1/20 0.49
RET P07949 1/20 0.49
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
FGFR1 P11362 1/20 0.49
PDGFRA P16234 1/20 0.49
FLT1 P17948 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3134722 0.91 TNK2 (0.65) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3135923 0.88 SYK (0.57) SYKTNK2MAP4K2ABL1BMX
SCHEMBL30338817 0.88 SYK (0.57) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3132833 0.85 SYK (0.59) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3831469 0.85 TNK2 (0.54) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3143228 0.85 KDR (0.52) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3139779 0.84 TNK2 (0.62) SYKTNK2MAP4K2ABL1BMX
SCHEMBL4876031 0.83 SYK (0.63) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3828971 0.83 TNK2 (0.52) SYKTNK2MAP4K2ABL1BMX
SCHEMBL3129666 0.82 TNK2 (0.50) SYKTNK2MAP4K2ABL1BMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US claimed
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-10-06 US claimed
US-20100234400-A1 COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS IRM LLC (BM) 2010-09-16 US disclosed
US-20100234400-A1 COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS IRM LLC (BM) 2010-09-16 US disclosed
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US disclosed
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US disclosed
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US disclosed
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234400-A1 COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS LIFR, ALPG, BMI1 SYK 4561/4885TNK2 3577/4885MAP4K2 2176/4885
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors BMX, FES, FRK SYK 11/4885TNK2 203/4885MAP4K2 37/4885
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BMX, FES, FRK SYK 11/4885TNK2 203/4885MAP4K2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.